Combination of trabectedin and irinotecan is highly effective in a human rhabdomyosarcoma xenograft

Anti-Cancer Drugs

Volumn 16, Issue 8, 2005, Pages 811-815

  Riccardi, Anna ^a   Meco, Daniela ^a   Ubezio, Paolo ^b   Mazzarella, Giorgio ^a   Marabese, Mirko ^b   Faircloth, Glynn T ^c   Jimeno, José ^d   D'Incalci, Maurizio ^b   Riccardi, Riccardo ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c PharmaMar USA Inc   (United States)

^d PHARMAMAR S A   (Spain)

Author keywords

Drug combination; Irinotecan; Rhabdomyosarcoma; SN 38; Trabectedin

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; DNA TOPOISOMERASE; DRUG METABOLITE; IRINOTECAN; TRABECTEDIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG SCREENING; GENETIC TRANSCRIPTION; HOST CELL; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHABDOMYOSARCOMA; TUMOR CELL; TUMOR VOLUME; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; DIOXOLES; DNA TOPOISOMERASES, TYPE I; HUMANS; ISOQUINOLINES; MALE; MICE; MICE, NUDE; RHABDOMYOSARCOMA; TETRAHYDROISOQUINOLINES; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 24044480041     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cad.0000172837.67766.6a     Document Type: Article

References (15)

1. Jin S, Gorfajn B, Faircloth G, Scotto KW. Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation. Proc Natl Acad Sci USA 2000; 97:6775-6779.
2. Minuzzo M, Marchini S, Broggini M, Faircloth G, D'Incalci M, Mantovani R. Interference of transcriptional activation by the antineoplastic drug Ecteinascidin-743. Proc Natl Acad Sci USA 2000; 97:6780-6784.
3. Damia G, Silvestri S, Carrassa L, Filiberti L, Faircloth GT, Liberi G, et al. Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways. Int J Cancer 2001; 92:583-588.
4. Li WW, Takahashi N, Jhanwar S, Cordon-Cardo C, Elisseyeff Y, Jimeno J, et al. Sensitivity of soft tissue sarcoma cell lines to chemotherapeutic agents: identification of ecteinascidin-743 as a potent cytotoxic agent. Clin Cancer Res 2001; 7:2908-2911.
5. Casanova M, Casali PG, Di Leo P, Bacci G, Ferrari A, Terenziani M, et al. Phase II study of 3-hour infusion of ET-743 (Ecteinascidin-743, Trabectedin, Yondelis) in pretreated adult and pediatric patients with small round cell sarcomas. Med Pediatr Oncol 2002; 39:287.
6. Yovine A, Riofrio M, Blay JY, Brain E, Alexandre J, Kahatt C, et al. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcomas patients. J Clin Oncol 2004; 22:890-899.
7. Garcia-Carbonero R, Supko JG, Manola J, Seiden MV, Harmon D, Ryan DP, et al. Phase II and pharmacokinetic study of ecteinascidin-743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol 2004; 22:1480-1490.
8. Meco D, Colombo T, Ubezio P, Zucchetti M, Zaffaroni M, Riccardi A, et al. Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies. Cancer Chemother Pharmacol 2003; 52:131-138.
9. Takahashi N, Li WW, Banerjee D, Scotto KW, Bertino JR. Sequence-dependent enhancement of cytotoxicity produced by Ecteinascidin 743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma cells. Clin Cancer Res 2001; 7:3251-3257.
10. D'Incalci M, Colombo N, Ubezio P, Nicoletti, Giavazzi, Erba E, et al. The combination of yondelis and cisplatin is synergistic against human tumor xenograft. Eur J Cancer 2003; 39:1920-1926.
11. Grasselli G, Malossi A, Colombo N, Perez C, D'Incalci M, Jimeno J, et al. Phase I and pharmacokinetic (PK) study of ecteinascidin-743 (ET743, Trabectedin) and cisplatin (P) combination in pre-treated patients (pts) with selected advanced solid tumors. Proc Am Soc Clin Oncol 2003; 22:542.
12. Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato K. Intracellular role of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 1991; 151:4187-4191.
13. Furman WL, Stewart CF, Poquette CA, Pratt CB, Santana VM, Zamboni WC, et al. Direct translation of a protracted irinotecan schedule from xenograft model to phase I trial in children. J Clin Oncol 1999; 17: 1815-1824.
14. Cosetti M, Wexler LH, Calleja E, Trippett T, LaQuaglia M, Huvos AG, et al. Irinotecan for pediatric solid tumors: the Memorial Sloan-Kettering experience. J Pediatr Hematol Oncol 2002; 24:101-105.
15. Allavena P, Signorelli M, Chieppa M, Erba E, Bianchi G, Marchesi F, et al. Anti- inflammatory properties of the novel anti-tumor agent Yondelis™ (trabectedin): inhibition of macrophage differentiation and cytokine production. Cancer Res 2005; 65:2964-2971.